Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 7 | -$1.26 | -$0.19 | -$0.69 |
| Q2 2026 | 7 | -$1.92 | -$0.53 | -$0.98 |
| Q3 2026 | 3 | -$1.02 | -$1.02 | -$1.02 |
| Q4 2026 | 3 | -$1.02 | -$1.02 | -$1.02 |
| Q1 2027 | 3 | -$0.92 | -$0.92 | -$0.92 |
| Q2 2027 | 2 | -$0.94 | -$0.94 | -$0.94 |
| Q3 2027 | 2 | -$0.96 | -$0.96 | -$0.96 |
| Q4 2027 | 2 | -$0.99 | -$0.99 | -$0.99 |
| Q1 2028 | 3 | $0.83 | $0.83 | $0.83 |
| Q2 2028 | 6 | $1.53 | $1.53 | $1.53 |
| Q3 2028 | 5 | $1.50 | $1.50 | $1.50 |
| Q4 2028 | 5 | $1.53 | $1.53 | $1.53 |
Immunic Inc last posted its earnings results on Wednesday, May 13th, 2026. The company reported $-1.08 earnings per share for the quarter, missing analysts' consensus estimates of $-0.71 by $0.37. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Immunic Inc has generated $-6 earnings per share over the last year ($-6.24 diluted earnings per share) and currently has a price-to-earnings ratio of -3.74. Immunic Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/13/2026 | Q1 2026 | -$0.71 | -$1.08 | -0.37 | $0 | $0 |
| 02/26/2026 | Q4 2025 | -$0.90 | -$1.60 | -0.7 | $0 | $0 |
| 11/13/2025 | Q3 2025 | -$0.18 | -$1.30 | -1.12 | $0 | $0 |
| 08/07/2025 | Q2 2025 | -$0.18 | -$2.00 | -1.82 | N/A | $0 |
| 05/15/2025 | Q1 2025 | -$0.25 | -$2.50 | -2.25 | N/A | $0 |
| 03/31/2025 | Q4 2024 | -$0.22 | -$2.80 | -2.58 | $6.00 K | $0 |
| 11/07/2024 | Q3 2024 | -$0.22 | -$2.40 | -2.18 | $6.00 K | $0 |
| 08/08/2024 | Q2 2024 | -$0.23 | -$2.10 | -1.87 | N/A | $0 |
| 05/08/2024 | Q1 2024 | -$0.27 | -$3.00 | -2.73 | N/A | $0 |
| 02/22/2024 | Q4 2023 | -$0.51 | -$4.80 | -4.29 | N/A | $0 |
| 09/29/2023 | Q3 2023 | N/A | -$5.10 | N/A | N/A | $0 |
| 08/03/2023 | Q2 2023 | -$0.52 | -$5.40 | -4.88 | N/A | $0 |
| 05/11/2023 | Q1 2023 | -$0.54 | -$5.30 | -4.76 | N/A | $0 |
| 02/23/2023 | Q4 2022 | -$0.82 | -$27.80 | -26.98 | N/A | $0 |
| 11/03/2022 | Q3 2022 | -$0.64 | -$7.30 | -6.66 | N/A | $0 |
| 08/04/2022 | Q2 2022 | -$0.72 | -$7.20 | -6.48 | N/A | $0 |
| 05/10/2022 | Q1 2022 | -$0.80 | -$7.20 | -6.4 | N/A | $0 |
| 02/24/2022 | Q4 2021 | -$0.73 | -$8.40 | -7.67 | N/A | $0 |
| 11/04/2021 | Q3 2021 | -$0.81 | -$7.60 | -6.79 | N/A | $0 |
| 08/06/2021 | Q2 2021 | -$0.72 | -$8.20 | -7.48 | N/A | $0 |
The conference call for Immunic Inc's latest earnings report can be listened to online.
The conference call transcript for Immunic Inc's latest earnings report can be read online.
Immunic Inc (:IMUX) has a recorded net income of $-97,172,000.Immunic Inc has generated $-6.24 earnings per share over the last four quarters.
Immunic Inc (:IMUX) has a price-to-earnings ratio of -3.74 and price/earnings-to-growth ratio is -0.07.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED